12 / 13
Page 53
N o v e m b e r 1 2 - 1 3 , 2 0 1 8 | R o m e , I t a l y
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Surgery and Anesthesia 2018 & Euro Gastro Congress 2018
Case Reports in Surgery and Invasive Procedures
|
Volume 2
&
GASTROENTEROLOGY
3
rd
International Conference on
SURGERY AND ANESTHESIA
International Conference on
Case Rep Surg Invasive Proced 2018, Volume 2
THE RESULT OF CLINICAL TRIAL FOR THE NEW LONAL DRUG FOR HEPATO-
PROTECTIVE EFFECT IN PATIENT WITH FATTY LIVER DISEASE WITH CHRONIC
HEPATITIS C
Ariunaa Z, Sarnai Ts, Erdenetsogt D
and
Badamjaw S
Research and Production Company of the Mong-Em, Mongolia
Introduction:
Following researchers determined the Chronic hepatitis C virus infection which was 8,2% (Davaalkham.J et al, 2003),
9,6%(Takahashi.M
et al, 2004
), 9,8% (Tsatsralt-Od.B
et al, 2006
), 11,8% (
Dagvadorj.Yaet al 2005
) in Mongolia. As researchers noted
that hepatitis C genotype 1 and 3 enable to be triglyceride accumulation for liver because it often occurs simultaneously fatty liver
disease. Although many types of traditional medicine have been used for for hundreds years, their effectiveness of the therapy is
relatively small with inadequate use of poorly understood in practice. These types of medicine’s storage, form, flavor are to improve
which are prepared based on scientific studying, is to make the clinical trial of drug acts as easily use, emerged as one of the need
for market. Therefore, our research team has made the clinical trial based on the chemical and pharmacological study of hepato-
protective effect for lonicera Altaica Pall fruit, an established clinical studies and producing new drugs.
Results:
Lonal drug decreases activation of syndrome hepatic cell cytolysis ALT (p=0.023), AST (p=0.037). Also decreases criteria
of cholestasis syndrome such as indirect bilirubin (p=0.611), ALP (p=0.04), GGT (p=0.445). The Lonal medicine was taken during
21 days and comparing the results of lipid metabolism exchange before and after treatment, reduces TG (p=0,402), increases
HDL (p=0.047). The participants have taken the Fibroscan analysis and liver biopsy. That was compared to determine before and
after treatment such as steatosis and fibrosis degree. Before treatment degree of steatosis was S2: 278.4±75.3 dB/m and after
treatment it was dropped from S1: 238.6±70.4 dB/m (p <0.05). And before treatment, such as fibrosis degree F2-3: 8.84 ± 2.2 kPa,
after treatment it was decreased in F1-2: 7.18 ± 3.87 (p<0.01). In liver histology, comparing before and after treatment the results
of liver cell inflammation-fibrosis area was reduced by 1,75 times and decreases hepatic steatosis degree (Strong fatty change was
improved Mild fatty change).
Conclusion:
New lonal medicine is reducing activation syndrome hepatic cell cytolysis, cholestatic and some criteria of the meta-
bolic syndrome in patient with fatty liver disease associated with chronic hepatitis C. Also new lonal medicine reduces the degree
of liver steatosis and fibrosis by the analysis of Fibroscan and liver biopsy.